Infliximab for refractory non-infectious uveitis: 10-year safety and steroid-sparing outcomes from an ophthalmology-led service

Background: To describe the real-world safety, steroid-sparing effect, treatment duration, infusion interval, and operational features of a medical ophthalmology-led biologic service managing non-infectious uveitis(NIU) patients with infliximab(IFX). Methods: Retrospective cohort review of patients receiving IFX for NIU at a tertiary NHS centre from March 2016 to March 2026. Primary outcomes were adverse events(AEs), serious adverse events(SAEs) and discontinuations; secondary outcomes were oral corticosteroid requirement and visual acuity. Results: 44 patients contributed 1208 months of IFX exposure (100.7 patient-years), with a median of 21.5 months(IQR 9.5–32.0). 37/44 (84%) had previously received adalimumab. AEs were reported by 20/44 (45%), including infections in 10/44 (23%) and rash in 9/44 (20%). SAEs occurred in 2/44 (5%): incident heart failure and anaphylaxis, each in 1/44 (2%). AEs led to discontinuation in 8/44 (18%). By 12 months, 10/44 (23%) had stopped IFX, most commonly due to ineffectiveness. Worse eye visual acuity changed by <15 ETDRS letters from baseline in 29/33 (88%), improved by ≥15 letters in 3/33 (9%), and worsened by ≥15 in 1/33 (3%). Among those using prednisolone at baseline, the median daily dose fell from 15 mg to 5.5 mg by month 12; at latest review (median 27 months) the median was 4.0 mg/day, with 18/21 (86%) taking ≤5 mg/day and 5/21 (24%) steroid-free. Conclusions: IFX was generally well tolerated and was associated with lower corticosteroid requirements in NIU. A medical ophthalmology-led biologic infusion service is feasible and safe but close collaboration with other medical specialties is critical for safe governance and delivery.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11197560/v1
Primary Topic
Ocular Diseases and Behçet’s Syndrome
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Infliximab for refractory non-infectious uveitis: 10-year safety and steroid-sparing outcomes from an ophthalmology-led service

James Benjamin Galloway, Carlos Eduardo Pavesio, David P. D’Cruz, Lawrence Langley et al.
Research Square
Ocular Diseases and Behçet’s Syndrome
preprint

Infliximab for refractory non-infectious uveitis: 10-year safety and steroid-sparing outcomes from an ophthalmology-led service

James Benjamin Galloway, Carlos Eduardo Pavesio, David P. D’Cruz, Lawrence Langley, Peter K. F. Addison, Jonathan Virgo, Tasanee Braithwaite, Vivi Riga, Shivaa Ramsewak, Aditi Sinha, Karindeep Kaur, Daniel Jackson
preprint en

Abstract

Background: To describe the real-world safety, steroid-sparing effect, treatment duration, infusion interval, and operational features of a medical ophthalmology-led biologic service managing non-infectious uveitis(NIU) patients with infliximab(IFX). Methods: Retrospective cohort review of patients receiving IFX for NIU at a tertiary NHS centre from March 2016 to March 2026. Primary outcomes were adverse events(AEs), serious adverse events(SAEs) and discontinuations; secondary outcomes were oral corticosteroid requirement and visual acuity. Results: 44 patients contributed 1208 months of IFX exposure (100.7 patient-years), with a median of 21.5 months(IQR 9.5–32.0). 37/44 (84%) had previously received adalimumab. AEs were reported by 20/44 (45%), including infections in 10/44 (23%) and rash in 9/44 (20%). SAEs occurred in 2/44 (5%): incident heart failure and anaphylaxis, each in 1/44 (2%). AEs led to discontinuation in 8/44 (18%). By 12 months, 10/44 (23%) had stopped IFX, most commonly due to ineffectiveness. Worse eye visual acuity changed by <15 ETDRS letters from baseline in 29/33 (88%), improved by ≥15 letters in 3/33 (9%), and worsened by ≥15 in 1/33 (3%). Among those using prednisolone at baseline, the median daily dose fell from 15 mg to 5.5 mg by month 12; at latest review (median 27 months) the median was 4.0 mg/day, with 18/21 (86%) taking ≤5 mg/day and 5/21 (24%) steroid-free. Conclusions: IFX was generally well tolerated and was associated with lower corticosteroid requirements in NIU. A medical ophthalmology-led biologic infusion service is feasible and safe but close collaboration with other medical specialties is critical for safe governance and delivery.

Research Square
St Thomas' Hospital (GB), Moorfields Eye Hospital NHS Foundation Trust (GB), King's College London (GB), Guy's and St Thomas' NHS Foundation Trust (GB), Western Eye Hospital (GB)
Good health and well-being
Ocular Diseases and Behçet’s Syndrome
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon